Loading...
XNAS
VTRS
Market cap18bUSD
Jul 09, Last price  
16.34USD
1D
-1.92%
1Q
21.31%
Name

Viatris Inc

Chart & Performance

D1W1MN
XNAS:VTRS chart
P/E
P/S
1.33
EPS
Div Yield, %
2.94%
Shrs. gr., 5y
14.26%
Rev. gr., 5y
3.66%
Revenues
14.30b
-2.98%
6,796,100,0006,909,100,0006,909,143,0007,719,600,0007,719,600,0009,429,300,0009,429,300,00011,076,900,00011,076,900,00011,907,700,00011,907,700,00011,433,900,00011,433,900,00011,500,500,00011,946,000,00017,886,300,00016,262,700,00015,426,900,00014,739,300,00014,299,900,000
Net income
-3.51b
L+454.23%
640,850,000623,700,000623,711,000929,400,000929,400,000847,600,000847,600,000480,000,000480,000,000696,000,000696,000,000352,500,000352,500,00016,800,000-669,900,000-1,269,100,0002,078,600,00054,700,000-634,200,000-3,514,900,000
CFO
2.32b
+0.56%
949,018,0001,106,600,0001,106,563,0001,014,800,0001,014,800,0002,008,500,0002,008,500,0002,047,200,0002,047,200,0002,064,800,0002,064,800,0002,341,700,0002,341,700,0001,803,700,0001,231,800,0003,016,900,0002,999,000,0002,799,600,0002,302,900,0002,315,900,000
Dividend
Nov 24, 20250.12 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
IPO date
Feb 01, 1973
Employees
38,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122018‑122017‑122017‑122016‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT